Ticker: VCEL

Company Overview Vericel Corporation (NASDAQ: VCEL) is a biopharmaceutical company based in Michigan that specializes in advanced therapies for sports medicine and severe burn care. Their portfolio includes MACI®, Epicel®, and NexoBrid®. Q2 2025 Financial Highlights Total Revenue: Increased to $...

Vericel Corporation (NASDAQ: VCEL) recently released its Q1 2025 financial results, showcasing a mixed performance in its income statement and several operational updates. Key Highlights: Total Revenue: $52.6 million, a 2.6% increase from $51.3 million in Q1 2024. Product Sales: Significant grow...